Get the latest delivered to your inbox
Privacy Policy

Now Reading

Impacting Human Health: 2022 ESG Report

Impacting Human Health: 2022 ESG Report

Published 06-23-23

Issued by Moderna


2022 was a pivotal year for Moderna. The last few years have demonstrated the profound potential of mRNA medicines to impact human health, and Moderna has evolved its Mission to deliver the greatest possible impact to people through mRNA medicines. In the second annual ESG Report, Moderna reflects on its commitments to tackle some of the biggest threats to human health, such as the urgent need to increase access to quality healthcare and medicines, inequalities affecting vulnerable communities around the world, and the increasing negative effects of climate change, and reports on how it advanced these strategies in 2022.

Report Highlights

In its 2022 ESG Report, Moderna provides an update on how it is advancing its ESG strategy against five guiding focus areas for ongoing and future efforts:

  • Medicines for patients
  • Employees
  • Environment
  • Community
  • Governance and ethics

The report also includes updates to the progress Moderna has made to date:

  • 156% increase in tracked volunteer hours from 2021
  • 63% employee participation rate in volunteering and/or giving
  • $7.8M in grants by the Moderna Foundation
  • $4M focused on improving health systems and healthcare in sub-Saharan Africa
  • Moderna also announced key progress in 2022 for its Global Public Health Strategy to:
    • Advance vaccines targeting 15 pathogens identified as the biggest public health risks into clinical studies by 2025 – 12 priority pathogens currently in research and development
    • Launch mRNA access – 9 institutions participating today
    • Expand regional manufacturing – 4 new facilities announced in Australia, Canada, Kenya, and the United Kingdom
  • The Company also announced reported on how, as it continues to scale as an organization, it is creating an environment that is rooted in a strong sense of belonging:      
    • Moderna’s team represents 34 different nationalities, and its workforce is 50 percent female with women comprising 41 percent of Moderna executives
    • Moderna also continued to work to increase racial and ethnic representation in its U.S. workforce in 2022
  • Understanding that human health and planetary health are interconnected, Moderna affirmed its prior commitments by establishing its environmental sustainability strategy based on three pillars.
    • Decarbonize value chain: Moderna has committed to define a near-term science-based target and evaluate a long-term Scope 3 target to minimize the impact to the environment from its value chain, establishing its 2021 GHG Scope 3 baseline
    • Natural resource conservation: Moderna has initiated internal energy audits to find efficiency opportunities and identify fossil fuel-fired equipment for replacement in pursuit of its net-zero carbon emissions commitment
    • Sustainability by design: Moderna has also committed to LEED certification (or equivalent) for new sites and buildings, targeting a 92% reduction in fossil fuel use and 10% reduction in embodied carbon in Moderna’s new HQ and R&D operations building in Cambridge, MA

To read more, please visit:

Media Contact:
Katherine O’Malley
Executive Director, Communications

Read More



In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit

Join today and get the latest delivered to your inbox